KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$2.2 million.

  • Amneal Pharmaceuticals' Change in Account Payables fell 12039.18% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 4305.1%. This contributed to the annual value of $54.4 million for FY2024, which is 45388.14% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Change in Account Payables is -$2.2 million, which was down 12039.18% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Account Payables registered a high of $34.1 million during Q4 2024, and its lowest value of -$7.2 million during Q2 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Change in Account Payables averaged around $3.5 million, with its median value being $1.7 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Change in Account Payables soared by 352666.67% in 2021, and later plummeted by 660533.33% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Account Payables (Quarter) stood at $1.6 million in 2021, then tumbled by 124.94% to -$407000.0 in 2022, then surged by 1493.61% to $5.7 million in 2023, then skyrocketed by 501.23% to $34.1 million in 2024, then crashed by 106.41% to -$2.2 million in 2025.
  • Its Change in Account Payables stands at -$2.2 million for Q3 2025, versus $6.4 million for Q2 2025 and -$1.1 million for Q1 2025.